• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Valneva SE - American Depositary Shares (NQ: VALN )

    4.331 +0.134 (+3.20%)
    Streaming Delayed Price Updated: 3:56 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Valneva SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
    Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
    Via Benzinga
    European And US Vaccine Stocks Are Under Pressure - Here's WHy
    Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
    Via Benzinga
    Exposures Product Safety
    Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Expert Ratings For Valneva
    Via Benzinga
    In-Depth Examination Of 6 Analyst Recommendations For Valneva
    Via Benzinga
    The Analyst Landscape: 6 Takes On Valneva
    Via Benzinga
    Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
    Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
    Via Benzinga
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Analyst Scoreboard: 8 Ratings For Valneva
    Via Benzinga
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024
    VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    3 Promising Biotech Stocks You Can Pick Up for Less Than $10
    Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. 
    Via InvestorPlace
    Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
    Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
    Via Benzinga
    The Analyst Landscape: 6 Takes On Valneva
    Via Benzinga
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
    Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Valneva
    Via Benzinga
    What Analysts Are Saying About Valneva Stock
    Via Benzinga
    VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
    VALN stock results show that Valneva missed on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
    VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
    U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Friday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Expert Ratings for Valneva
    Via Benzinga
    Analyst Ratings for Valneva
    Via Benzinga
    Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
    Valneva sells FDA Priority Review Voucher for $103 million after FDA approval of Ixchiq, the world's first licensed chikungunya vaccine. Proceeds to boost R&D projects. 
    Via Benzinga
    Exposures Product Safety
    McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
    With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
    Via Benzinga
    Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
    Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.